Evidence map›Paper›PMID 35732452›Full record

ArticleInternal medicine (Tokyo, Japan)2023

Rheumatoid Arthritis Symptoms Diagnosed by Rheumatic Immune-related Adverse Events Caused by Nivolumab in a Patient with Esophageal Cancer.

Sho Yasui, Akira Yoshida, Miki Takata, Yu Kamitani, Yusuke Nakada, Hiroki Kurumi, Yuichiro Ikebuchi, Koichiro Kawaguchi, Kazuo Yashima, Hajime Isomoto

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Efficacy and safety ofWorld journal of clinical cases · 2025
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sho YasuiDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Akira YoshidaDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Miki TakataDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan.
Yu KamitaniDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Yusuke NakadaDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Hiroki KurumiDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Yuichiro IkebuchiDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Koichiro KawaguchiDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Kazuo YashimaDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Hajime IsomotoDivision of Gastroenterology and Nephrology, Faculty of Medicine, Tottori University, Japan.
Tottori University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report described the case of a 70-year-old man who developed polyarthralgia after nivolumab treatment for recurrent esophageal cancer. Arthritis developed after initiating nivolumab therapy, and the patient tested positive for rheumatoid factor and anti-citrullinated peptide antibodies. The hand and elbow joints were already deformed, suggesting that he had had rheumatoid arthritis for several years and that the symptoms had only become apparent after nivolumab administration. This patient had rheumatoid arthritis, which was diagnosed as a nivolumab-induced rheumatic immune-related adverse event (rh-irAEs). Arthralgia during nivolumab administration can occur in rh-irAE cases. Patients should be assessed for autoimmune diseases before initiating immune checkpoint inhibitors.

Indexed as

Arthritis, RheumatoidEsophageal NeoplasmsAgedHumansMaleNivolumabNivolumabesophageal cancernivolumabrheumatic immune-related adverse eventsrheumatoid arthritistalaporfin sodium photodynamic therapy

Identifiers

PMID35732452
PMCPMC9908395
OpenAlexW4283362569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.